Abstract:Abstract Background: Breast Cancer (BC) patients exhibit a wide variety of responses to neoadjuvant chemotherapy (NACT). This is driven by factors both intrinsic (e.g., mutations, dysregulation, metabolic reprogramming) and extrinsic (e.g., nutrient/drug perfusion, interactions with surrounding healthy tissues and the tumor microenvironment (TME)) to the cells that make up each tumor. The SimBioSys TumorScope is a platform for making individualized predictions of the response of each patient's tumor to NACT. It employs 3D biophysical simulations that explicitly model the dynamics of cellular response to the ever-changing chemical milieu of drugs and nutrients that perfuse the TME during treatment, in order to predict when and where different regions of the tumor are growing, dying, and ultimately how a given patient will respond to treatment. Methods: The SimBioSys TumorScope constructs 3D in silico models of each patient's tumor directly from pretreatment DCE-MRIs. It combines this spatial model with personalized genome-scale models of tumor and tissue metabolism, pharmacokinetics, and pharmacodynamics, and vascular perfusion (based on DCE-MRI timeseries). The combined model is then simulated using a custom high-performance reaction-diffusion-material mechanics simulation engine which produces a spatio-temporal trajectory of tumor size, morphology, intra- and extracellular biochemistry. We evaluated the ability of the TumorScope software to predict volumetric response to NACT. A validation set comprising the pretreatment records (including MRIs) of 780 BC patients that underwent NACT was used. These patients spanned a wide range of tumor sizes, molecular subtypes, and NCCN-recommended treatment regimens. Simulations were initialized using each patient’s pretreatment MRI and pathology data and run from the start of therapy to the specified surgical date. Simulated tumor volumetric percent response (calculated as the ratio of change in tumor volume to initial volume) at the time of surgery was then compared with actual tumor volumetric percent response extracted from presurgical MRIs. Among patients for which event free survival data was available (n = 480), we performed a Cox proportional hazard analysis. Results: The SimBioSys TumorScope predicted pre-surgical tumor volumetric response with a median error of 0.03% and median absolute deviation of 8.2%. Among the patients for which EFS data was available, we found a hazard ratio of 1.8 associated with having a final simulated volume greater than 0.01 cc (p = 0.00048). Conclusions: The SimBioSys TumorScope produces accurate patient specific predictions of response to NACT using only standard-of-care pre-treatment data. Such predictions can aid in decision making, enabling physicians to select less-toxic regimens for patients in which a robust response is predicted, and more aggressive treatments and/or clinical trial enrollment when response is likely to be poor. Citation Format: John A Cole, Jr., Joseph R Peterson, Tyler M Earnest, Michael J Hallock, Daniel J Cook, Eduardo Braun, Anu Antony, John R Pfeiffer, Tushar Pandey. Simbiosys tumorscope: Biophysical modeling of patient-specific response to chemotherapy [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-08-31.

Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

Systems-based Digital Twins to Help Characterize Clinical Dose-Response and Propose Predictive Biomarkers in a Phase I Study of Bispecific Antibody, Mosunetuzumab, in NHL.

Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1)

Harnessing the predictive power of preclinical models for oncology drug development

The Pharmacokinetic/Pharmacodynamic Pipeline: Translating Anticancer Drug Pharmacology to the Clinic

Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data

Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials.

Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools

Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology

Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development

Assessing clinical response in early oncology development with a predictive biomarker

Abstract 2826: Examples of translational preclinical models to mimic cancer drug resistance

Abstract 6892: Murine ex vivo platform: A powerful tool for biomarker assessment and high throughput screening of translationally relevant in vivo tumor models for PD and efficacy studies

Abstract P1-08-31: Simbiosys tumorscope: Biophysical modeling of patient-specific response to chemotherapy

Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development

Retrospective Assessment of Translational Pharmacokinetic–Pharmacodynamic Modeling Performance: A Case Study with Apitolisib, a Dual PI3K/mTOR Inhibitor

Computational Predictions of Nonclinical Pharmacokinetics at the Drug Design Stage

Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology